Mostrar el registro sencillo del ítem

dc.contributor.author
Srinivasan, Venkatramanujam  
dc.contributor.author
Kaur, Charanjit  
dc.contributor.author
Pandi Perumal, Seithikurippu R.  
dc.contributor.author
Brown, Gregory M.  
dc.contributor.author
Cardinali, Daniel Pedro  
dc.date.available
2023-03-29T12:14:50Z  
dc.date.issued
2011-03  
dc.identifier.citation
Srinivasan, Venkatramanujam; Kaur, Charanjit; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.; Cardinali, Daniel Pedro; Melatonin and its agonist ramelteon in Alzheimer's disease: Possible therapeutic value; Hindawi Publishing Corporation; International Journal of Alzheimer's Disease; 2011; 3-2011; 1-15  
dc.identifier.issn
2090-0252  
dc.identifier.uri
http://hdl.handle.net/11336/191948  
dc.description.abstract
Alzheimer's disease (AD) is an age-associated neurodegenerative disease characterized by the progressive loss of cognitive function, loss of memory and insomnia, and abnormal behavioral signs and symptoms. Among the various theories that have been put forth to explain the pathophysiology of AD, the oxidative stress induced by amyloid β-protein (Aβ) deposition has received great attention. Studies undertaken on postmortem brain samples of AD patients have consistently shown extensive lipid, protein, and DNA oxidation. Presence of abnormal tau protein, mitochondrial dysfunction, and protein hyperphosphorylation all have been demonstrated in neural tissues of AD patients. Moreover, AD patients exhibit severe sleep/wake disturbances and insomnia and these are associated with more rapid cognitive decline and memory impairment. On this basis, the successful management of AD patients requires an ideal drug that besides antagonizing Aβ-induced neurotoxicity could also correct the disturbed sleep-wake rhythm and improve sleep quality. Melatonin is an effective chronobiotic agent and has significant neuroprotective properties preventing Aβ-induced neurotoxic effects in a number of animal experimental models. Since melatonin levels in AD patients are greatly reduced, melatonin replacement has the potential value to be used as a therapeutic agent for treating AD, particularly at the early phases of the disease and especially in those in whom the relevant melatonin receptors are intact. As sleep deprivation has been shown to produce oxidative damage, impaired mitochondrial function, neurodegenerative inflammation, and altered proteosomal processing with abnormal activation of enzymes, treatment of sleep disturbances may be a priority for arresting the progression of AD. In this context the newly introduced melatonin agonist ramelteon can be of much therapeutic value because of its highly selective action on melatonin MT1/MT2 receptors in promoting sleep.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Hindawi Publishing Corporation  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Alzheimers disease  
dc.subject
Melatonin  
dc.subject
Mild Cognitive Impairment  
dc.subject
sleep  
dc.subject.classification
Fisiología  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Melatonin and its agonist ramelteon in Alzheimer's disease: Possible therapeutic value  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-03-28T14:20:19Z  
dc.journal.volume
2011  
dc.journal.pagination
1-15  
dc.journal.pais
Reino Unido  
dc.description.fil
Fil: Srinivasan, Venkatramanujam. No especifíca;  
dc.description.fil
Fil: Kaur, Charanjit. No especifíca;  
dc.description.fil
Fil: Pandi Perumal, Seithikurippu R.. No especifíca;  
dc.description.fil
Fil: Brown, Gregory M.. University of Toronto; Canadá  
dc.description.fil
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.journal.title
International Journal of Alzheimer's Disease  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/ijad/2011/741974/  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.4061/2011/741974